Trial · NCT01246973
Oral Curcumin for Radiation Dermatitis
NCT01246973, Phase 2, Phase 3, Completed, University of Rochester; results first posted 2016-03-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oral Curcumin for Radiation Dermatitis. Trials, record NCT01246973. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01246973
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Curcumin for Radiation Dermatitis
- NCT number
- NCT01246973
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 686 participants, actual
- Lead sponsor
- University of Rochester
- Conditions
- Radiation-induced Dermatitis
- Interventions
- Curcumin, Placebo
- First posted
- 2010-11-24
- Last updated
- 2016-03-07
- Results first posted
- 2016-03-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Radiation Dermatitis Severity Score | 6 weeks | The outcome measures will be the severity of radiation dermatitis, using the Radiation Dermatitis Score (RDS), at the end of treatment in each treatment arm. (Objective: To examine the efficacy of curcumin in preventing and/or reducing the severity of dermatitis in radiation treatment site in breast cancer patients). The RDS score ranges from 0-4 with higher scores indicating worse outcome. |
| Secondary | Percentage of Subjects With Moist Desquamation | 6 weeks | Moist desquamation was measured by the presence of wet, patchy crusting, oozing, or ulcerated skin in areas where skin was peeling in sheets. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Radiation Dermatitis Severity Score | 6 weeks | units on a scale | MEAN | |
| SECONDARY | Percentage of Subjects With Moist Desquamation | 6 weeks | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Radiation Dermatitis Severity Score | Curcumin | 2.02 | Standard Deviation 0.05 | units on a scale | |
| Mean Radiation Dermatitis Severity Score | Placebo | 1.99 | Standard Deviation 0.06 | units on a scale | |
| Percentage of Subjects With Moist Desquamation | Curcumin | 9.541 | percentage of participants | ||
| Percentage of Subjects With Moist Desquamation | Placebo | 12.203 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Curcumin | 344 | |
| Overall Study | STARTED | Placebo | 342 | |
| Overall Study | COMPLETED | Curcumin | 283 | |
| Overall Study | COMPLETED | Placebo | 295 | |
| Overall Study | NOT COMPLETED | Curcumin | 61 | |
| Overall Study | NOT COMPLETED | Placebo | 47 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Curcumin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Curcumin | 0 | 344 |
| Total, other adverse events | Placebo | 0 | 342 |
| Total, serious adverse events | Curcumin | 0 | 344 |
| Total, serious adverse events | Placebo | 0 | 342 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA037420 | University of Rochester Cancer Center CCOP Research Base | MORROW, GARY R | UNIVERSITY OF ROCHESTER | NATIONAL CANCER INSTITUTE | 1985 to 2014 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Curcumin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01246973
GET https://conductscience.org/api/trials/v1/NCT01246973/registered